DOCSLIB.ORG

Session Outline Gastric Epithelial Polyps

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Session Outline Gastric Epithelial Polyps Gastric Neoplasia: Subtypes, Staging, and Ancillary testing Rish K. Pai MD, PhD Professor of Laboratory Medicine & Pathology Mayo Clinic Arizona Florida Society of Pathology Summer 2019 [email protected] ©2017 MFMER | slide-1 1 Session Outline • Gastric Epithelial Polyps, including Unusual Types • An Update on the Classification and Staging of Gastric Carcinoma • Ancillary Testing in Gastric Carcinoma 2 2 Gastric Epithelial Polyps Most Common Polyp Types • Fundic gland polyp (~75%) • Gastric hyperplastic polyp (~20%) • Polypoid adenocarcinoma (~2%) Infrequently Encountered Polyp Types • Adenoma (~1%) – Intestinal type, foveolar type, oxyntic gland adenoma, pyloric gland adenoma • Hamartomatous polyp (<<1%) – Juvenile polyp, Peutz‐Jegher polyp, Cowden syndrome • All fairly indistinguishable from sporadic gastric hyperplastic polyp 3 1. Carmack SW et al. Am J Gastroenterol 2009;104:1524-1532. 3 Fundic Gland Polyp • Most common gastric polyp (~75% of all polyps). Sporadic Syndromic Fundic Gland Polyp Fundic Gland Polyp Increasing incidence due to proton pump inhibitor Familial adenomatous polyposis (FAP) therapy and GERD GAPPS (Gastric adenocarcinoma and proximal polyposis syndrome) Women > Men Women = Men Solitary or multiple (40%) Typically multiple (90%) Mean age ~50 years Mean age ~40 years (any fundic gland polyp in a child should prompt evaluation for FAP) CTNNB1 (ß‐catenin) mutation (90%) >>> APC (10%) APC mutation >> CTNNB1 (ß‐catenin) Low risk of dysplasia (<1%) High risk of dysplasia (~50%) (most studies indicate FAP patients do not develop adenocarcinoma) 4 1. Arnason T et al. Histopathology 2014;65:353-362. 4 Fundic Gland Polyp with Low‐Grade Dysplasia in FAP Patient 5 5 Fundic Gland Polyp in FAP Patient 6 6 Fundic Gland Polyp with Low‐Grade Dysplasia in FAP Patient 7 7 Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) • Early onset presentation (youngest 10 years, earliest gastric cancer at age 33 years). • Autosomal dominant inherited fundic gland polyposis of the body and fundus (>100 polyps in index patient or >30 in first degree relative). • No colorectal or duodenal polyposis. • High rate of progression to intestinal‐type gastric adenocarcinoma. • Due to point mutations in the promoter 1B of the APC gene. 1. Worthley DL et al. Gut 2012;61:774-779. 2. Li J et al. Am J Hum Genet 2016;98:830-842 8 3. McDuffie LA et al. J Clin Pathol 2016;69:826-833. 8 Gastrectomy Specimen from ~39 year old woman (no known prior genetic disorder) subsequently found to have point mutation in APC promoter 1B 9 9 GAPPS: Proximal Fundic Gland Polyposis 10 10 GAPPS: Proximal Fundic Gland Polyposis 11 11 Oxyntic Gland Polyp/Adenoma • Rare, usually solitary, and exclusively located in the gastric fundus or body. • Histologic Features: – Crowded glands or irregular anastomosing cords of oxyntic epithelial cells involving the deep mucosal glands. – Mixture of chief cells (predominate), parietal cells, and mucous neck cells. – MUC6 positive, MUC5AC negative, MUC2 negative. – Pitfall: synaptophysin can be positive (Don’t mistake for a neuroendocrine tumor!) • Prognosis – Most studies indicate that these do not progress to invasive adenocarcinoma, although literature is limited. 1. Singhi A et al. Am J Surg Pathol 2012;36:1030-1035. 2. Hidaka Y et al. Hum Pathol 2013;44:2438-2448. 12 3. Chan K et al. Histopathology 2016;Histopathology 68:825-833. 12 Oxyntic Gland Polyp / Adenoma: Chief cell predominant 13 13 Oxyntic Gland Polyp / Adenoma: Crowded Deep Glands 14 14 Oxyntic Gland Polyp / Adenoma: Chief cell predominant 15 15 Gastric Hyperplastic Polyp • Most often in older patient (6th to 7th decade) with equal gender distribution. • Clinical Associations: – Helicobacter gastritis (if non‐polypoid mucosa is not sampled, I order Helicobacter IHC to evaluate if there is active inflammation with abundant plasma cells). – Chemical gastritis / reactive gastropathy (bile reflux). – Gastroesophageal reflux disease (GERD) if located in the cardia • Histologic Features: – Cystically dilated glands with elongated foveolar epithelium with “corkscrew” appearance. – Stromal edema and chronic inflammation. – Surface erosion and ulceration is common. – Intestinal metaplasia and dysplasia can occur. 16 1. Horvath B et al. Int J Surg Pathol 2016;24:704-708. 16 Gastric Hyperplastic Polyp with Low‐Grade Dysplasia 17 17 Gastric Hyperplastic Polyp with Low‐Grade Dysplasia 18 18 Gastric Hyperplastic Polyp with Low‐Grade Dysplasia 19 19 Differential Diagnosis of Gastric Hyperplastic Polyp Polypoid foveolar hyperplasia • Smaller than hyperplastic polyps. • Foveolar elongation and corkscrewing without cystic change to the glands or stromal edema. Mucosal prolapse type polyp • Antral/pylorus location. • Foveolar elongation with mild cystic change, prominent vertical smooth muscle hyperplasia, and thick walled vessels within the mucosa. 20 Gonzalez-Obeso E et al. Am J Surg Pathol 2011;35:670-677. 20 Juvenile Polyposis • Juvenile polyps can be virtually indistinguishable from gastric hyperplastic polyps. • ~40% cumulative lifetime risk of developing colorectal cancer and 10‐15% cumulative lifetime risk of gastric cancer. • “Hyperplastic” polyp in young patients, especially if multiple, should be evaluated for the possibility of a hamartomatous polyposis syndrome. • Due to germline mutation in genes involved in the transforming growth factor (TGF) β signalling pathway: – SMAD4 • Increased propensity for polyps in upper GI tract, particularly the stomach. • Polyps with epithelial component >> stromal component. • More likely to develop carcinoma. – BMPR1A 21 Gastrectomy Specimen from 32 year old woman (no known prior genetic disorder) 22 Epithelial Predominant Juvenile Polyp 23 Epithelial Predominant Juvenile Polyp 24 Loss of SMAD4 by Immunohistochemistry: Juvenile Polyposis due to germline SMAD4 mutation 25 Am J Clin Pathol 2017;147:390-398. Histopathology 2017;70:918-928 • Combined total of 31 patients presenting with massive gastric juvenile‐ type polyposis. • Median age 48 years (range 13 to 79 years). • Loss of SMAD4 expression in 25 of 29 cases (86%). • High frequency of gastric epithelial neoplasia: – 7 of 31 (23%) with gastric carcinoma. – 9 of 31 (29%) with dysplasia. • 18 of 31 patients had a known history of juvenile polyposis. • Of the patients without a history of juvenile polyposis, five of six patients had germline testing demonstrating a SMAD4 germline mutation. 26 Gastric Adenoma • Rare (~1% of all gastric polyps). • Intestinal‐type adenoma (more common) – Arise in a background of intestinal metaplasia. – Often have intermixed Paneth cells (which may be prominent) and endocrine cells. – MUC2 positive (IHC not necessary for diagnosis). • Foveolar‐type adenoma (less common) – Characteristic apical mucin cap within the cytoplasm. – MUC5AC positive, MUC6 negative, MUC2 negative. • Therapy: Complete endoscopic removal. 27 27 Gastric Adenoma, Intestinal Type, with Low‐Grade Dysplasia 28 28 Gastric Adenoma, Intestinal Type, with Low‐Grade Dysplasia 29 29 Gastric Adenoma, Foveolar Type, with Low‐Grade Dysplasia 30 30 Gastric Adenoma, Foveolar Type, with Low‐Grade Dysplasia: Note the characteristic apical mucin cap 31 31 Gastric Adenoma, Foveolar Type, with High‐Grade Dysplasia 32 32 Pyloric Gland Adenoma • Occur in the stomach (all sites) and duodenum. • Women >> men for gastric lesions; mean age 73 years. • Histologic features: – Closely packed glands with a monolayer of cuboidal epithelial cells. – Pale to eosinophilic “ground glass” cytoplasm. – No apical mucin cap (in contrast to gastric foveolar adenoma). – Diffuse MUC6 positivity with MUC5AC positivity seen on surface. 1. Chen Z et al. Am J Surg Pathol 2009;33:186-193. 2. Vieth M et al. Virchows Arch 2003;442:317-321. 3. Wood LD et al. Am J Surg Pathol 2014;38:389-393. 4. Hackeng W et al. Histopathology 2016;70:549-557. 5. Lee S et al. Am J Surg Pathol 2014;38:784-792. 33 6. Choi WT et al Histopathology. 2018 May;72(6):1007‐1014. 33 Pyloric Gland Adenoma 34 34 Pyloric Gland Adenoma Pyloric Gland Adenoma: “Ground Glass” eosinophilic cytoplasm with no apical mucin cap 35 35 Pyloric Gland Adenoma: “Ground Glass” eosinophilic cytoplasm with no apical mucin cap 36 36 Pyloric Gland Adenoma • Clinical Associations: – 60% are associated with a background of intestinal metaplasia. – 40% are associated with autoimmune atrophic gastritis – increased risk of HGD in this setting – Seen in patients with familial adenomatous polyposis (FAP). – Rarely seen in patients with Lynch syndrome. • ~50% have high‐grade dysplasia and ~10% can progress to invasive adenocarcinoma. 1. Chen Z et al. Am J Surg Pathol 2009;33:186-193. 2. Vieth M et al. Virchows Arch 2003;442:317-321. 3. Wood LD et al. Am J Surg Pathol 2014;38:389-393. 4. Hackeng W et al. Histopathology 2016;70:549-557. 5. Lee S et al. Am J Surg Pathol 2014;38:784-792. 37 6. Choi WT et al. Histopathology. 2018 May;72(6):1007‐1014. 37 Pyloric Gland Adenoma Feature Low‐Grade Dysplasia High‐Grade Dysplasia Cytology • Preserved nuclear polarity • Loss of nuclear polarity • Inconspicuous nucleoli or • Prominent, enlarged nucleoli only occasional enlarged • Nuclear size variation nucleoli • Uniform nuclear size Architecture • Closely packed tubular glands • Complex glandular architecture including cribriform glands and intraluminal papillary tufts 38 1. Chen Z et al. Am J Surg Pathol 2009;33:186-193. 38 Pyloric Gland Adenoma with High‐Grade Dysplasia (cribriform architecture, nuclear enlargement, prominent nucleoli, increased mitotic activity) 39 39 Pyloric
Load more

Recommended publications
  • Table of Contents
    ANTICANCER RESEARCH International Journal of Cancer Research and Treatment ISSN: 0250-7005 Volume 32, Number 4, April 2012 Contents Experimental Studies * Review: Multiple Associations Between a Broad Spectrum of Autoimmune Diseases, Chronic Inflammatory Diseases and Cancer. A.L. FRANKS, J.E. SLANSKY (Aurora, CO, USA)............................................ 1119 Varicella Zoster Virus Infection of Malignant Glioma Cell Cultures: A New Candidate for Oncolytic Virotherapy? H. LESKE, R. HAASE, F. RESTLE, C. SCHICHOR, V. ALBRECHT, M.G. VIZOSO PINTO, J.C. TONN, A. BAIKER, N. THON (Munich; Oberschleissheim, Germany; Zurich, Switzerland) .................................... 1137 Correlation between Adenovirus-neutralizing Antibody Titer and Adenovirus Vector-mediated Transduction Efficiency Following Intratumoral Injection. K. TOMITA, F. SAKURAI, M. TACHIBANA, H. MIZUGUCHI (Osaka, Japan) .......................................................................................................... 1145 Reduction of Tumorigenicity by Placental Extracts. A.M. MARLEAU, G. MCDONALD, J. KOROPATNICK, C.-S. CHEN, D. KOOS (Huntington Beach; Santa Barbara; Loma Linda; San Diego, CA, USA; London, ON, Canada) ...................................................................................................................................... 1153 Stem Cell Markers as Predictors of Oral Cancer Invasion. A. SIU, C. LEE, D. DANG, C. LEE, D.M. RAMOS (San Francisco, CA, USA) ................................................................................................
    [Show full text]
  • Clinical Silence of Pulmonary Lymphoepithelioma-Like Carcinoma with Subcutaneous Metastasis
    Shima et al. World Journal of Surgical Oncology (2019) 17:128 https://doi.org/10.1186/s12957-019-1671-z CASEREPORT Open Access Clinical silence of pulmonary lymphoepithelioma-like carcinoma with subcutaneous metastasis: a case report Takafumi Shima1, Kohei Taniguchi1,2* , Yasutsugu Kobayashi3, Shotaro Kakimoto4, Nagahisa Fujio5 and Kazuhisa Uchiyama1 Abstract Background: Dissemination of lung cancer to cutaneous sites usually results in a poor prognosis. Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare tumor, and no therapeutic strategy for it has yet been established. We present herein an extremely rare case of a long-term surviving patient with PLELC showing subcutaneous metastasis. Case presentation: A76-year-oldwomanwasdiagnosedunexpectedlyashavingPLELCbasedonanodule on her back. After surgical resection of the primary and metastatic lesions, she has remained alive with no recurrence for over 5 years without any additional therapy. Conclusion: Even in the case of PLELC with subcutaneous metastasis, surgical management may afford a prognosis of long-term survival. Keywords: Lymphoepithelioma-like carcinoma, Lung cancer, Cutaneous metastasis, Epstein-Barr virus Background a lipoma, and so tumorectomy was performed as usual Lung cancer with cutaneous metastases represents a with no other preoperative inspection. A specimen of grave disease with poor prognostic [1]. Pulmonary lym- the tumor revealed a subcutaneous solid tumor measur- phoepithelioma-like carcinoma (PLELC) is a rare form ing 40 × 40 mm (Fig. 1a, b). Hematoxylin and eosin (HE) of cancer that shares morphological similarities to undif- staining showed evidence of malignant spindle-cell pro- ferentiated nasopharyngeal carcinoma, and there is no liferation (Fig. 1c). Also, immunohistochemistry (IHC) unified therapeutic strategy for it [2, 3].
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Adenoid Cystic Carcinoma of Salivary Glands - Diagnostic and Prognostic Factors and Treatment Outcome Recent Publications in This Series
    KAROLIINA HIRVONEN Adenoid Cystic Carcinoma of Salivary Glands - Diagnostic and Prognostic Factors and Treatment Outcome Glands - Diagnostic Carcinoma of Salivary KAROLIINA HIRVONEN Adenoid Cystic Recent Publications in this Series 39/2017 Mari Teesalu Uncovering a Sugar Tolerance Network: SIK3 and Cabut as Downstream Effectors of Mondo-Mlx 40/2017 Katriina Tarkiainen Pharmacogenetics of Carboxylesterase 1 41/2017 Noora Sjöstedt DISSERTATIONES SCHOLAE DOCTORALIS AD SANITATEM INVESTIGANDAM In Vitro Evaluation of the Pharmacokinetic Effects of BCRP Interactions UNIVERSITATIS HELSINKIENSIS 59/2017 42/2017 Jenni Hällfors Nicotine Dependence — Identifying the Contribution of Specific Genes 43/2017 Marjaana Pussila Cancer-preceding Gene Expression Changes in Mouse Colon Mucosa 44/2017 Ansku Holstila Changes in Leisure-Time Physical Activity, Functioning, Work Disability and Retirement: KAROLIINA HIRVONEN A Follow-Up Study among Employees 45/2017 Jelena Meinilä Diet Quality and Its Association with Gestational Diabetes Adenoid Cystic Carcinoma of Salivary Glands: 46/2017 Martina B. Lorey Diagnostic and Prognostic Factors and Secretome Analysis of Human Macrophages Activated by Microbial Stimuli 47/2017 Eeva Suvikas-Peltonen Treatment Outcome Lääkkeiden turvallisen käyttökuntoon saattamisen edistäminen sairaaloiden osastoilla 48/2017 Pedro Alexandre Bento Pereira The Human Microbiome in Parkinson’s Disease and Primary Sclerosing Cholangitis 49/2017 Mira Sundström Urine Testing and Abuse Patterns of Drugs and New Psychoactive Substances — Application
    [Show full text]
  • Lymphoepithelioma Like Carcinoma of Kidney – a Rare Entity
    CASE REPORT LYMPHOEPITHELIOMA LIKE CARCINOMA OF KIDNEY – A RARE ENTITY. Susruthan M1, Rajesh H2, Rajendiran S3 HOW TO CITE THIS ARTICLE: Susruthan M, Rajesh H, Rajendiran S. “Lymphoepithelioma like carcinoma of kidney – a rare entity”. Journal of Evolution of Medical and Dental Sciences 2013; Vol. 2, Issue 47, November 25; Page: 9163-9166. INTRODUCTION: Lymphoepithelioma, otherwise known as poorly differentiated carcinoma commonly occurs in nasopharynx. Tumors with similar morphology occur at salivary gland, stomach, thymus, urogenital system and lung which are known as Lymphoepithelioma like carcinoma (LELC) Its incidence in kidney is extremely rare. We describe here a report, to our knowledge, the seventh case of Lymphoepithelioma like carcinoma occurring in kidney (LELC). CASE PRESENTATION: A 65 years old woman presented with left flank pain for three months. CT abdomen revealed a mass of size 5.2x5x4cm in the upper pole of kidney with heterogeneous contrast enhancement. Left radical nephrectomy was performed. On microscopy two cell populations were present, one being large atypical cells positive for cytokeratin and other being lymphoid cells showing CD 3 positivity. A final diagnosis of lymphoepithelioma like carcinoma of kidney pT3 N2a cM0 was rendered. DISCUSSION: LELC is distinguished from xanthogranulomatous pyelonephritis by the nests of cytokeratin positive large cells with prominent nucleoli in a lymphoid background. Cytokeratin negativity in Non Hodgkin’s Lymphoma helps in the distinction of LELC from lymphomas. LELCs are distinguished from collecting duct carcinoma by the absence of desmoplasia and marked cytological atypia. The right diagnosis is vital since treatment regimens, prognostic factors and survival rates vary. CASE REPORT: INTRODUCTION: Lymphoepithelioma, otherwise known as poorly differentiated carcinoma is a common tumor occurring in the nasopharynx, related in most cases to Epstein Barr virus.
    [Show full text]
  • FNA of Tumors of Unknown Primary in the Head and Neck Jeffrey F
    FNA of Basaloid Neoplasms of the Head and Neck Jeffrey F. Krane, MD PhD Professor of Pathology David Geffen School of Medicine at UCLA Overview • Case based approach • Basaloid tumors and closely related entities • Review – Common clinical presentations – Cytologic features – Adjunctive techniques as appropriate Basaloid Tumors • Sparse cytoplasm confers an immature appearance • Need to rely on other clues to classify – Chromatin – Matrix – Architecture/Smear pattern – Non-basaloid areas Two Main Scenarios • Basaloid salivary gland tumors • Basaloid metastases in neck lymph nodes Salivary Gland Tumors Salivary gland neoplasms Clinical Management • Superficial parotid gland is most common site • Benign tumor/Low-grade carcinoma Excision of the mass (partial parotidectomy) • High-grade carcinoma Radical surgery (complete parotidectomy) Neck dissection? Radiation therapy Challenging Salivary Gland Patterns Benign/LG Malignant HG Malignant • Oncocytic/Clear cell • High-grade • Spindle cell • Cystic/Mucinous Basaloid neoplasms Basaloid pattern is most problematic Differential diagnosis spans benign, low-grade and high-grade carcinomas Case 1: History • A 79 year-old woman with a 5 month history of a firm, mobile 2 cm non-tender parotid mass. Case 1 Case 1 Case 1 Case 1 Case 1 Case 1 Case 1: Diagnosis? A. Adenoid cystic carcinoma B. Basal cell adenoma C. Skin adnexal neoplasm D. Basaloid squamous cell carcinoma Case 1 Case 1: Diagnosis? Basal cell adenoma, membranous type Basaloid neoplasms: Differential Diagnosis • Benign: Basal cell adenoma,
    [Show full text]
  • Lymphoepithelioma-Like Carcinoma of the Skin: a Case (--THIS SECTION DOES NOT PRINT--)
    QUICK DESIGN GUIDE QUICK TIPS (--THIS SECTION DOES NOT PRINT--) Lymphoepithelioma-like Carcinoma of the Skin: A Case (--THIS SECTION DOES NOT PRINT--) This PowerPoint 2007 template produces a 36”x48” professional poster. Of One Individual Presenting with Two Primary Cutaneous Neoplasms This PowerPoint template requires basic PowerPoint It will save you valuable time placing titles, subtitles, text, and (version 2007 or newer) skills. Below is a list of graphics. commonly asked questions specific to this template. Jacqueline C. Fisher, DO, Rachel M. White, BA, and Daniel S. Hurd, DO, FAOCD If you are using an older version of PowerPoint some Use it to create your presentation. Then send it to LewisGale Hospital Montgomery / Edward Via College of Osteopathic Medicine template features may not work properly. PosterPresentations.com for premium quality, same day affordable printing. Using the template Case Report Merkel cell carcinoma (MCC) can present clinically similar to LELCS but will stain positive for We provide a series of online tutorials that will guide you through the Figures 1 neuroendocrine markers such as synaptophysin, neuron-specific enolase, and CK20. In Verifying the quality of your graphics poster design process and answer your poster production questions. An 83-year-old Caucasian female was referred to our dermatology clinic for surgical excision of a addition, peripheral lymphocytic infiltrate is usually absent in MCC.2,14Clarke and Ioffreda previously biopsied lesion on her left neck reported initially as a nodular basal cell carcinoma with Go to the VIEW menu and click on ZOOM to set your report a case in which LELCS demonstrates spindle shaped cells that resemble the spindle cell focal morpheaform features.
    [Show full text]
  • Lymphoepithelioma-Like Carcinoma of the Skin: a Case of One Patient Presenting with Two Primary Cutaneous Neoplasms
    Lymphoepithelioma-like Carcinoma of the Skin: A Case of One Patient Presenting with Two Primary Cutaneous Neoplasms Jacqueline C. Fisher, DO,* Rachel M. White, BA,** Daniel S. Hurd, DO, FAOCD*** *Dermatology Resident, PGY-2, VCOM/LewisGale Hospital Montgomery, Blacksburg, VA **Medical Student, OMS IV, Philadelphia College of Osteopathic Medicine, Philadelphia, PA ***Dermatology Residency Program Director, VCOM/LewisGale Hospital Montgomery, Blacksburg, VA Abstract Lymphoepithelioma-like carcinoma of the skin (LELCS) is a rare cutaneous neoplasm most frequently found on the head and neck of elderly patients. Debate exists regarding its histogenesis, but it’s believed to be of epithelial origin. Histologically, LELCS is remarkably similar to undifferentiated nasopharyngeal carcinoma, a neoplasm associated with Epstein-Barr virus (EBV) infection. EBV reactivity is the main distinguishing factor between these two cutaneous neoplasms, with LELCS rarely documented to test positive for EBV. In general, those diagnosed with LELCS are advised to undergo evaluation of the nasopharynx as well as other internal organ systems that may harbor a lymphoepithelioma-like carcinoma to exclude cutaneous metastasis. Current treatment guidelines recommend wide local excision or Mohs micrographic surgery to prevent local recurrence of LELCS. To the best of the authors’ knowledge, this case is the first to report a patient with two separate lymphoepithelioma-like carcinomas of the skin presenting simultaneously. Introduction Case Report neck and left parietal scalp neoplasms showed Lymphoepithelioma-like carcinoma of the skin An 83-year-old Caucasian female was referred a dermal proliferation of atypical epithelioid (LELCS) is a rare cutaneous neoplasm with low to our dermatology clinic for surgical excision cells forming well-defined nests invested by malignant potential.
    [Show full text]
  • Second Revised Proposed Regulation of the State
    SECOND REVISED PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 February 5, 2018 EXPLANATION – Matter in italics is new; matter in brackets [omitted material] is material to be omitted. AUTHORITY: §§1, 2, 4-9 and 11-15, NRS 457.065 and 457.240; §3, NRS 457.065 and 457.250; §10, NRS 457.065; §16, NRS 439.150, 457.065, 457.250 and 457.260. A REGULATION relating to cancer; revising provisions relating to certain publications adopted by reference by the State Board of Health; revising provisions governing the system for reporting information on cancer and other neoplasms established and maintained by the Chief Medical Officer; establishing the amount and the procedure for the imposition of certain administrative penalties by the Division of Public and Behavioral Health of the Department of Health and Human Services; and providing other matters properly relating thereto. Legislative Counsel’s Digest: Existing law defines the term “cancer” to mean “all malignant neoplasms, regardless of the tissue of origin, including malignant lymphoma and leukemia” and, before the 78th Legislative Session, required the reporting of incidences of cancer. (NRS 457.020, 457.230) Pursuant to Assembly Bill No. 42 of the 78th Legislative Session, the State Board of Health is: (1) authorized to require the reporting of incidences of neoplasms other than cancer, in addition to incidences of cancer, to the system for reporting such information established and maintained by the Chief Medical Officer; and (2) required to establish an administrative penalty to impose against any person who violates certain provisions which govern the abstracting of records of a health care facility relating to the neoplasms the Board requires to be reported.
    [Show full text]
  • Conversion of Morphology of ICD-O-2 to ICD-O-3
    NATIONAL INSTITUTES OF HEALTH National Cancer Institute to Neoplasms CONVERSION of NEOPLASMS BY TOPOGRAPHY AND MORPHOLOGY from the INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY, SECOND EDITION to INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY, THIRD EDITION Edited by: Constance Percy, April Fritz and Lynn Ries Cancer Statistics Branch, Division of Cancer Control and Population Sciences Surveillance, Epidemiology and End Results Program National Cancer Institute Effective for cases diagnosed on or after January 1, 2001 TABLE OF CONTENTS Introduction .......................................... 1 Morphology Table ..................................... 7 INTRODUCTION The International Classification of Diseases for Oncology, Third Edition1 (ICD-O-3) was published by the World Health Organization (WHO) in 2000 and is to be used for coding neoplasms diagnosed on or after January 1, 2001 in the United States. This is a complete revision of the Second Edition of the International Classification of Diseases for Oncology2 (ICD-O-2), which was used between 1992 and 2000. The topography section is based on the Neoplasm chapter of the current revision of the International Classification of Diseases (ICD), Tenth Revision, just as the ICD-O-2 topography was. There is no change in this Topography section. The morphology section of ICD-O-3 has been updated to include contemporary terminology. For example, the non-Hodgkin lymphoma section is now based on the World Health Organization Classification of Hematopoietic Neoplasms3. In the process of revising the morphology section, a Field Trial version was published and tested in both the United States and Europe. Epidemiologists, statisticians, and oncologists, as well as cancer registrars, are interested in studying trends in both incidence and mortality.
    [Show full text]
  • Lymphoepithelioma-Like Carcinoma in Liver Not Associated with Epstein-Barr Virus: a Report of 3 Cases and Literature Review
    Zhang et al. Diagnostic Pathology (2020) 15:115 https://doi.org/10.1186/s13000-020-01035-6 CASE REPORT Open Access Lymphoepithelioma-like carcinoma in liver not associated with Epstein-Barr virus: a report of 3 cases and literature review Kai Zhang1†, Changcheng Tao1†, Zonggui Tao2, Fan Wu1, Songlin An3, Jianxiong Wu1* and Weiqi Rong1* Abstract Background: Lymphoepithelioma-like carcinoma is a rare distinctive variant of liver cancer with unique epidemiological and pathological characteristics, characterized by dense lymphocyte infiltration. It can be divided into lymphoepithelioma-like hepatocellular carcinoma and lymphoepithelioma-like intrahepatic cholangiocarcinoma. Existing research shows that the prognosis of this tumor is good. To date, only 101 cases have been reported. Case presentation: The first patient was a 62-year-old Chinese man with hepatitis B virus infection who presented with a single lesion in the liver. The patient underwent surgical treatment and was discharged on the 4th day. The patient was diagnosed with combined lymphoepithelioma-like hepatocellular carcinoma and cholangiocarcinoma; he has been alive for 15 months. The second patient was a 63-year-old Chinese woman with right upper abdominal pain and hepatitis B virus infection. The imaging examination revealed a single lesion in the liver. The patient underwent surgical treatment and was discharged 1 week later. The patient was diagnosed with lymphoepithelioma-like hepatocellular carcinoma and was considered to have recurrence in the lymph nodes approximately 2 years after the operation. The patient underwent local radiotherapy; she has been alive for 60 months. The third patient was a 50-year-old Chinese man with hepatitis B virus infection who presented with a single lesion in the liver and two enlarged lymph nodes.
    [Show full text]
  • Effective for Cases Diagnosed January 1, 2016 and Later
    POLICY AND PROCEDURE MANUAL FOR REPORTING FACILITIES May 2016 Effective For Cases Diagnosed January 1, 2016 and Later Indiana State Cancer Registry Indiana State Department of Health 2 North Meridian Street, Section 6-B Indianapolis, IN 46204-3010 TABLE OF CONTENTS INDIANA STATE DEPARTMENT OF HEALTH STAFF ............................................................................. viii INDIANA STATE DEPARTMENT OF HEALTH CANCER REGISTRY STAFF .......................................... ix ACKNOWLEDGMENTS ................................................................................................................................ x INTRODUCTION ........................................................................................................................................... 1 A. Background ..................................................................................................................................... 1 B. Purpose .......................................................................................................................................... 1 C. Definitions ....................................................................................................................................... 1 D. Reference Materials........................................................................................................................ 1 E. Consultation .................................................................................................................................... 2 F. Output ............................................................................................................................................
    [Show full text]